ALX ONCOLOGY HOLDINGS INC

Insider sell of 2,230 shares by CEO Jason Lettmann shows routine tax‑planning, not a warning, amid ALX’s bullish 150% rally and solid immuno‑oncology pipeline.

Insider sale of 565 ALX Oncology shares by finance VP Pinto Shelly shows a routine tax‑savings move, not a loss of confidence in the company’s high‑growth immuno‑oncology strategy.

ALX Oncology insider sale: Pinto Shelly sells 3,925 shares at $1.11—an ordinary tax‑planning move, not a red flag, while executive buying fuels confidence in the company’s pipeline.